Northwestern University Jun 30 2026 Reviewed Northwestern Medicine scientists have demonstrated that a highly sensitive blood test can detect traces of pancreatic cancer missed by standard testing, potentially helping physicians identify patients whose disease is more likely to return even when scans appear reassuring. The sensitive blood test focuses on KRAS, a genetic mutation that drives more than 90% of pancreatic cancers. The findings come as a new revolutionary drug targeting KRAS is